- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2021
- 50 Pages
China
From €2481EUR$2,600USD£2,079GBP
- Report
- February 2024
- 172 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2022
- 65 Pages
Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- June 2022
- 142 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- June 2022
- 65 Pages
Africa, Middle East
From €1432EUR$1,500USD£1,199GBP
- Report
- September 2024
- 218 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- October 2024
- 98 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
- 102 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2022
- 100 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- September 2024
- 112 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- May 2022
- 284 Pages
Global
From €3298EUR$3,456USD£2,764GBP
- Book
- September 2018
Asia Pacific

The Intravenous Anesthetic market is a subset of the Anesthetic Drugs market, which includes drugs used to induce and maintain anesthesia. Intravenous anesthetics are administered intravenously and are used to induce general anesthesia, sedation, and analgesia. These drugs are typically used in surgical procedures, as well as in intensive care units and emergency departments. Intravenous anesthetics are typically administered in combination with other drugs, such as opioids, benzodiazepines, and neuromuscular blocking agents.
Intravenous anesthetics are typically classified as either barbiturates or propofol. Barbiturates are used to induce general anesthesia and are typically used in combination with other drugs. Propofol is a short-acting intravenous anesthetic that is used to induce and maintain general anesthesia.
Some companies in the Intravenous Anesthetic market include Fresenius Kabi, Baxter International, Hospira, and B. Braun Melsungen. Show Less Read more